SuperworthOcular Therapeutix OCUL
- Market cap
- $1.4B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 27.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $52.1M
- −8% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −17.9%
Ocular Therapeutix trades at 27.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $52.1M over the last twelve months, down 8% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $15.1M+26% | $14.8M+5% | $14.8M+11% | $16.4M+8% | $15.4M+2% | $17.1M+15% | $10.7M−28% | $13.5M−18% | $14.5M−6% | $13.3M−22% | $10.8M+1% | $13.5M+0% | |
| Cost of revenue | $1.4M+28% | $1.4M+37% | $1.3M+9% | $1.5M+16% | $1.6M+13% | $1.2M−11% | $1.3M−5% | $1.9M+29% | $1.8M+14% | $1.6M+30% | $1.3M+5% | $2M+3% |
| Gross profit | $13.7M+26% | $13.4M+3% | $13.4M+11% | $14.9M+8% | $13.9M+1% | $15.9M+18% | $9.4M−30% | $11.5M−23% | $12.8M−8% | $11.7M−27% | $9.5M+0% | $11.5M−0% |
| R&D | $15M+10% | $16.2M+20% | $20.7M+41% | $28.9M+91% | $37.1M+147% | $41M+153% | $42.9M+107% | $51.1M+77% | $52.4M+41% | $50.8M+24% | $66.2M+55% | $54.1M+6% |
| SG&A | $17.9M−4% | $17.3M−9% | $24.3M+22% | $29.7M+53% | $22.8M+27% | $25.4M+47% | $30.5M+25% | $28.1M−5% | $29.1M+28% | $30.6M+20% | $36.6M+20% | $39.4M+41% |
| −$19.2M−11% | −$20.1M+4% | −$31.6M+40% | −$43.6M+112% | −$46M+139% | −$50.6M+152% | −$63.9M+102% | −$67.6M+55% | −$68.7M+49% | −$69.8M+38% | −$93.3M+46% | −$82.1M+21% | |
| Interest expense | $3.4M+91% | $4.2M+125% | $4.1M+129% | $3.2M+61% | $3.2M−6% | $3.1M−25% | $3M−26% | $3M−6% | $3M−7% | $2.8M−9% | $2.8M−7% | $2.8M−7% |
| Net income | −$516K−98% | −$29.2M+88% | −$64.8M+114% | −$43.8M+112% | −$36.5M+6972% | −$48.4M+66% | −$64.1M−1% | −$67.8M+55% | −$69.4M+90% | −$64.7M+34% | −$88.6M+38% | −$78.8M+16% |
| −$0.25−19% | −$0.35+75% | −$0.49+26% | −$0.26+0% | −$0.22−12% | −$0.29−17% | −$0.38−22% | −$0.39+50% | −$0.38+73% | −$0.29+0% | −$0.40+5% | −$0.35−10% | |
| 85.1M+11% | 84.4M+10% | 132M+71% | 165.8M+113% | 167M+96% | 168M+99% | 169.4M+28% | 172.6M+4% | 183.9M+10% | 222.5M+32% | 224.1M+32% | 225M+30% |
Revenue: Q1 FY14: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY14: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY14: 6 months less the 3 months printed beside them. 49 periods, Q2 FY14 to Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
SG&A: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Operating income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
Net income: Q1 FY13 and Q1 FY14: 6 months less the 3 months printed beside them.
EPS, diluted: 10 periods, Q1 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY13: share-days: the 6-month average less the second quarter's. 13 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Ocular Therapeutix's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OCULOcular Therapeutix | $1.4B | n/m | n/a | 27.4× | −8% | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| Peer median | $1.5B | 14.1× | 19.9× | 1.8× | +14% | 10.9% |
More on Ocular Therapeutix
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .